{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T12:00:23Z","timestamp":1790078423163,"version":"4.0.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:00:00Z","timestamp":1790035200000},"content-version":"vor","delay-in-days":83,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"The CAPTRA-STAR Research Grant Program 2025"},{"name":"Noncommunicable Chronic Diseases-National Science and Technology Major Project","award":["2026ZD0553706"],"award-info":[{"award-number":["2026ZD0553706"]}]},{"name":"Beijing Cancer Prevention and Research Association","award":["KY202502055"],"award-info":[{"award-number":["KY202502055"]}]},{"name":"The Beijing High-level Innovation and Entrepreneurship Talent Support Program leading talent projects","award":["G202512054"],"award-info":[{"award-number":["G202512054"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"DOI":"10.1186\/s12916-026-05026-0","type":"journal-article","created":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T08:57:26Z","timestamp":1782896246000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Evaluation and analysis of renal injury in patients with advanced renal cell carcinoma receiving first-line benmelstobart plus anlotinib: results from the ETER100 study"],"prefix":"10.1186","volume":"24","author":[{"given":"Juan","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huichun","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huayan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xieqiao","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bixia","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siming","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaowen","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihong","family":"Chi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuanliang","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Si","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinan","family":"Sheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,1]]},"reference":[{"issue":"1","key":"5026_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2017.9","volume":"3","author":"JJ Hsieh","year":"2017","unstructured":"Hsieh JJ, Purdue MP, Signoretti S, Swanton C, Albiges L, Schmidinger M, et al. Renal cell carcinoma. Nat Rev Dis Primers. 2017;3(1):17009.","journal-title":"Nat Rev Dis Primers"},{"issue":"2","key":"5026_CR2","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.annonc.2023.09.3108","volume":"35","author":"XQ Yan","year":"2024","unstructured":"Yan XQ, Ye MJ, Zou Q, Chen P, He ZS, Wu B, et al. Toripalimab plus axitinib versus sunitinib as first-line treatment for advanced renal cell carcinoma: RENOTORCH, a randomized, open-label, phase III study. Ann Oncol. 2024;35(2):190\u20139.","journal-title":"Ann Oncol"},{"issue":"14","key":"5026_CR3","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1056\/NEJMoa2035716","volume":"384","author":"R Motzer","year":"2021","unstructured":"Motzer R, Alekseev B, Rha SY, Porta C, Eto M, Powles T, et al. Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma. N Engl J Med. 2021;384(14):1289\u2013300.","journal-title":"N Engl J Med"},{"issue":"12","key":"5026_CR4","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","volume":"380","author":"I Rini Brian","year":"2019","unstructured":"Rini Brian I, Plimack Elizabeth R, Stus V, Gafanov R, Hawkins R, Nosov D, et al. Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med. 2019;380(12):1116\u201327.","journal-title":"N Engl J Med"},{"issue":"10189","key":"5026_CR5","doi-asserted-by":"publisher","first-page":"2404","DOI":"10.1016\/S0140-6736(19)30723-8","volume":"393","author":"BI Rini","year":"2019","unstructured":"Rini BI, Powles T, Atkins MB, Escudier B, McDermott DF, Suarez C, et al. Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial. Lancet. 2019;393(10189):2404\u201315.","journal-title":"Lancet"},{"key":"5026_CR6","doi-asserted-by":"crossref","unstructured":"Dutcher JP, Flippot R, Fallah J, Escudier B On the Shoulders of Giants: The Evolution of Renal Cell Carcinoma Treatment\u2014Cytokines, Targeted Therapy, and Immunotherapy. Am Soc Clin Oncol Educ Book. 2020 (40):418\u201335.","DOI":"10.1200\/EDBK_280817"},{"issue":"3","key":"5026_CR7","doi-asserted-by":"publisher","first-page":"e006361","DOI":"10.1136\/jitc-2022-006361","volume":"11","author":"BI Rini","year":"2023","unstructured":"Rini BI, Brugarolas J, Atkins MB. Navigating and adapting care integrating immunotherapy, antiangiogenic therapy, and combinations in patients with advanced renal cell carcinoma. J Immunother Cancer. 2023;11(3):e006361.","journal-title":"J Immunother Cancer"},{"key":"5026_CR8","doi-asserted-by":"crossref","unstructured":"Bor\u00f3wka M, \u0141\u0105cki-Zynzeling S, Nicze M, Kozak S, Chudek J Adverse Renal Effects of Anticancer Immunotherapy: A Review. Cancers (Basel). 2022;14(17).","DOI":"10.3390\/cancers14174086"},{"issue":"6","key":"5026_CR9","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1007\/s00280-021-04260-y","volume":"87","author":"Mielczarek \u0141","year":"2021","unstructured":"Mielczarek \u0141, Brodziak A, Sobczuk P, Kawecki M, Cudnoch-J\u0119drzejewska A, Czarnecka AM. Renal toxicity of targeted therapies for renal cell carcinoma in patients with normal and impaired kidney function. Cancer Chemother Pharmacol. 2021;87(6):723\u201342.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"12","key":"5026_CR10","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1038\/bjc.2016.147","volume":"114","author":"MJ Sorich","year":"2016","unstructured":"Sorich MJ, Rowland A, Kichenadasse G, Woodman RJ, Mangoni AA. Risk factors of proteinuria in renal cell carcinoma patients treated with VEGF inhibitors: a secondary analysis of pooled clinical trial data. Br J Cancer. 2016;114(12):1313\u20137.","journal-title":"Br J Cancer"},{"issue":"2","key":"5026_CR11","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1161\/HYPERTENSIONAHA.117.10271","volume":"71","author":"AK Pandey","year":"2018","unstructured":"Pandey AK, Singhi EK, Arroyo JP, Ikizler TA, Gould ER, Brown J, et al. Mechanisms of VEGF (Vascular Endothelial Growth Factor) Inhibitor-Associated Hypertension and Vascular Disease. Hypertension. 2018;71(2):e1\u2013e8.","journal-title":"Hypertension"},{"issue":"21","key":"5026_CR12","doi-asserted-by":"publisher","first-page":"2993","DOI":"10.1200\/JCO.2007.11.5113","volume":"25","author":"WJ van Heeckeren","year":"2007","unstructured":"van Heeckeren WJ, Ortiz J, Cooney MM, Remick SC. Hypertension, proteinuria, and antagonism of vascular endothelial growth factor signaling: clinical toxicity, therapeutic target, or novel biomarker? J Clin Oncol. 2007;25(21):2993\u20135.","journal-title":"J Clin Oncol"},{"issue":"4","key":"5026_CR13","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1161\/HYPERTENSIONAHA.109.149690","volume":"56","author":"MH Kappers","year":"2010","unstructured":"Kappers MH, van Esch JH, Sluiter W, Sleijfer S, Danser AH, van den Meiracker AH. Hypertension induced by the tyrosine kinase inhibitor sunitinib is associated with increased circulating endothelin-1 levels. Hypertension. 2010;56(4):675\u201381.","journal-title":"Hypertension"},{"issue":"6","key":"5026_CR14","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1111\/j.1523-1755.2004.00621.x","volume":"65","author":"BF Schrijvers","year":"2004","unstructured":"Schrijvers BF, Flyvbjerg A, De Vriese AS. The role of vascular endothelial growth factor (VEGF) in renal pathophysiology. Kidney Int. 2004;65(6):2003\u201317.","journal-title":"Kidney Int"},{"issue":"3","key":"5026_CR15","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1016\/j.kint.2016.04.008","volume":"90","author":"FB Cortazar","year":"2016","unstructured":"Cortazar FB, Marrone KA, Troxell ML, Ralto KM, Hoenig MP, Brahmer JR, et al. Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors. Kidney Int. 2016;90(3):638\u201347.","journal-title":"Kidney Int"},{"issue":"4","key":"5026_CR16","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1053\/j.ajkd.2019.03.433","volume":"74","author":"R Shingarev","year":"2019","unstructured":"Shingarev R, Glezerman IG. Kidney Complications of Immune Checkpoint Inhibitors: A Review. Am J Kidney Dis. 2019;74(4):529\u201337.","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"5026_CR17","doi-asserted-by":"publisher","first-page":"130","DOI":"10.34067\/KID.0000852019","volume":"1","author":"S Gupta","year":"2020","unstructured":"Gupta S, Cortazar FB, Riella LV, Leaf DE. Immune Checkpoint Inhibitor Nephrotoxicity: Update 2020. Kidney360. 2020;1(2):130\u201340.","journal-title":"Kidney360"},{"issue":"2","key":"5026_CR18","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1159\/000455014","volume":"45","author":"R Wanchoo","year":"2017","unstructured":"Wanchoo R, Karam S, Uppal NN, Barta VS, Deray G, Devoe C, et al. Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review. Am J Nephrol. 2017;45(2):160\u20139.","journal-title":"Am J Nephrol"},{"key":"5026_CR19","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1196793","volume":"14","author":"YN Feng","year":"2023","unstructured":"Feng YN, Xie GY, Xiao L, Mo DC, Huang JF, Luo PH, et al. Severe and fatal adverse events of immune checkpoint inhibitor combination therapy in patients with metastatic renal cell carcinoma: a systematic review and meta-analysis. Front Immunol. 2023;14:1196793.","journal-title":"Front Immunol"},{"issue":"1","key":"5026_CR20","doi-asserted-by":"publisher","first-page":"40","DOI":"10.3904\/kjim.2014.29.1.40","volume":"29","author":"SH Baek","year":"2014","unstructured":"Baek SH, Kim H, Lee J, Kim DK, Oh KH, Kim YS, et al. Renal adverse effects of sunitinib and its clinical significance: a single-center experience in Korea. Korean J Intern Med. 2014;29(1):40\u20138.","journal-title":"Korean J Intern Med"},{"issue":"8","key":"5026_CR21","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1097\/CAD.0000000000000253","volume":"26","author":"FX Nouhaud","year":"2015","unstructured":"Nouhaud FX, Pfister C, Defortescu G, Giwerc A, Charbit D, Gouerant S, et al. Baseline chronic kidney disease is associated with toxicity and survival in patients treated with targeted therapies for metastatic renal cell carcinoma. Anticancer Drugs. 2015;26(8):866\u201371.","journal-title":"Anticancer Drugs"},{"issue":"8","key":"5026_CR22","doi-asserted-by":"publisher","first-page":"338.e1","DOI":"10.1016\/j.urolonc.2016.03.010","volume":"34","author":"H Fukuda","year":"2016","unstructured":"Fukuda H, Kondo T, Iida S, Takagi T, Tanabe K. Treatment-related deterioration of renal function is associated with the antitumor efficacy of sunitinib in patients with metastatic renal cell carcinoma. Urol Oncol. 2016;34(8):338.e1\u20139.","journal-title":"Urol Oncol"},{"issue":"4","key":"5026_CR23","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1159\/000447179","volume":"10","author":"H Miyake","year":"2017","unstructured":"Miyake H, Imai S, Ozono S, Fujisawa M. The Inverse Association between the Baseline Renal Function and Overall Survival in Patients with Metastatic Renal Cell Carcinoma Treated with Molecular-Targeted Agents. Curr Urol. 2017;10(4):186\u201392.","journal-title":"Curr Urol"},{"issue":"1","key":"5026_CR24","doi-asserted-by":"publisher","DOI":"10.1177\/1073274820977143","volume":"27","author":"H Zhang","year":"2020","unstructured":"Zhang H, Zhang X, Zhu X, Ni Y, Dai J, Zhu S, et al. The Impact of Renal Impairment on Survival Outcomes in Patients With Metastatic Renal Cell Carcinoma Treated With Tyrosine Kinase Inhibitors. Cancer Control. 2020;27(1):1073274820977143.","journal-title":"Cancer Control"},{"issue":"3","key":"5026_CR25","doi-asserted-by":"publisher","first-page":"386","DOI":"10.21037\/tau-21-1015","volume":"11","author":"K Ning","year":"2022","unstructured":"Ning K, Wu Z, Zou X, Liu H, Wu Y, Xiong L, et al. Immune checkpoint inhibitors further aggravate proteinuria in patients with metastatic renal cell carcinoma after long-term targeted therapy. Transl Androl Urol. 2022;11(3):386\u201396.","journal-title":"Transl Androl Urol"},{"issue":"9","key":"5026_CR26","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1016\/S1470-2045(25)00343-2","volume":"26","author":"A Zhou","year":"2025","unstructured":"Zhou A, Shen P, Li J, Qu W, Wang Z, Ren X, et al. First-line benmelstobart plus anlotinib versus sunitinib in advanced renal cell carcinoma (ETER100): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2025;26(9):1145\u201357.","journal-title":"Lancet Oncol"},{"issue":"6","key":"5026_CR27","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1007\/s00345-023-04407-x","volume":"41","author":"AJ Tan","year":"2023","unstructured":"Tan AJ, Mo DC, Wu K, Pan HM, Wang DM, Xu XX, et al. Nephrotoxicity of immune checkpoint inhibitor combination therapy in patients with advanced renal cell carcinoma: a meta-analysis. World J Urol. 2023;41(6):1563\u201371.","journal-title":"World J Urol"},{"issue":"1","key":"5026_CR28","doi-asserted-by":"publisher","first-page":"121","DOI":"10.2215\/CJN.05610522","volume":"18","author":"A Rashidi","year":"2023","unstructured":"Rashidi A, Wanchoo R, Izzedine H. How I Manage Hypertension and Proteinuria Associated with VEGF Inhibitor. Clin J Am Soc Nephrol. 2023;18(1):121\u20133.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"5026_CR29","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1681\/ASN.2019070676","volume":"31","author":"FB Cortazar","year":"2020","unstructured":"Cortazar FB, Kibbelaar ZA, Glezerman IG, Abudayyeh A, Mamlouk O, Motwani SS, et al. Clinical Features and Outcomes of Immune Checkpoint Inhibitor-Associated AKI: A Multicenter Study. J Am Soc Nephrol. 2020;31(2):435\u201346.","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"5026_CR30","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.kint.2018.01.023","volume":"94","author":"MA Perazella","year":"2018","unstructured":"Perazella MA, Dreicer R, Rosner MH. Renal cell carcinoma for the nephrologist. Kidney Int. 2018;94(3):471\u201383.","journal-title":"Kidney Int"},{"issue":"5","key":"5026_CR31","first-page":"500","volume":"377","author":"MH Rosner","year":"2017","unstructured":"Rosner MH, Perazella MA. Acute Kidney Injury in Patients with Cancer. N Engl J Med. 2017;377(5):500\u20131.","journal-title":"N Engl J Med"},{"issue":"2","key":"5026_CR32","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s40620-016-0311-8","volume":"30","author":"L Cosmai","year":"2017","unstructured":"Cosmai L, Gallieni M, Liguigli W, Porta C. Renal toxicity of anticancer agents targeting vascular endothelial growth factor (VEGF) and its receptors (VEGFRs). J Nephrol. 2017;30(2):171\u201380.","journal-title":"J Nephrol"},{"key":"5026_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2024.102692","volume":"125","author":"M Tucci","year":"2024","unstructured":"Tucci M, Cosmai L, Pirovano M, Campisi I, Re SGV, Porta C, et al. How to deal with renal toxicities from immune-based combination treatments in metastatic renal cell carcinoma. A nephrological consultation for Oncologists. Cancer Treat Rev. 2024;125:102692.","journal-title":"Cancer Treat Rev"},{"issue":"3","key":"5026_CR34","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1007\/s00280-018-3762-x","volume":"83","author":"L He","year":"2019","unstructured":"He L, Li J, Zhan J, Yi F, Fan X, Wei Y, et al. The value of serum cystatin C in early evaluation of renal insufficiency in patients undergoing chemotherapy: a systematic review and meta-analysis. Cancer Chemother Pharmacol. 2019;83(3):561\u201371.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"12","key":"5026_CR35","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1016\/j.annonc.2025.08.007","volume":"36","author":"BI Rini","year":"2025","unstructured":"Rini BI, Albiges L, Tang X, Koeppen H, Bex A, Su\u00e1rez C, et al. Circulating kidney injury molecule-1 (KIM-1) and association with outcome to adjuvant immunotherapy in renal cell carcinoma. Ann Oncol. 2025;36(12):1525\u201334.","journal-title":"Ann Oncol"},{"issue":"1","key":"5026_CR36","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s11255-009-9608-z","volume":"42","author":"SS Soni","year":"2010","unstructured":"Soni SS, Cruz D, Bobek I, Chionh CY, Nalesso F, Lentini P, et al. NGAL: a biomarker of acute kidney injury and other systemic conditions. Int Urol Nephrol. 2010;42(1):141\u201350.","journal-title":"Int Urol Nephrol"}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12916-026-05026-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-026-05026-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-026-05026-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T11:03:44Z","timestamp":1790075024000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12916-026-05026-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,1]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5026"],"URL":"https:\/\/doi.org\/10.1186\/s12916-026-05026-0","relation":{},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,1]]},"assertion":[{"value":"20 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This post-hoc analysis was approved by the Medical Ethics Committee of Peking University Cancer Hospital (approval number: 2026KT96). This post-hoc analysis used de-identified data collected from the ETER100 trial, for which all participants had provided written informed consent before enrolment; therefore, additional informed consent was not required.","order":1,"name":"Ethics","label":"Ethical approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"507"}}